*For more details about COVID-19 therapeutics and vaccines, diagnostic products and clinical trial delays, go to BioWorld Snapshots.

The drumbeat of innovation in the heart valves space continues as companies pursue next-generation devices for easier implantation, to improve durability and to treat younger patients. Even though ...

South San Francisco-based Trex Bio Inc. priced its IPO of about 8.3 million shares at $14 per share for about $116.7 million to finance efforts taking aim at a pair of targets hardly unfamiliar to the ...

Ono Pharmaceutical Co. Ltd. is paying $100 million up front to gain select Asian rights to Biohaven Ltd.’s small-molecule IgG degrader portfolio, including in Japan, South Korea and Taiwan, as it ...

Neurizon Therapeutics Ltd. has advanced NUZ-001 (monepantel) from a 12-patient proof-of-concept study into a fully enrolled, ...

Several initiatives the U.S. Department of Health and Human Services (HHS) announced Oct. 8 continue to shift the government’s vaccine focus from disease prevention to vaccine harm. Strengthening “how ...

In the last five years, public markets in Europe have been a no-go area for biotechs, and for U.K. companies the situation is dire, with the way barred to new entrants and a lack of liquidity leading ...

Persistent mycobacterial infections may depend on senescent macrophages that provide a long-term intracellular refuge to survive as a reservoir. Based on this concept, researchers from the University ...

Simcere Pharmaceutical Co. Ltd. has divulged bicyclic compounds acting as lysosomal acid glucosylceramidase (GBA; β-glucocerebrosidase) positive allosteric modulators reported to be useful for the ...

Viatris Inc. plans to discuss the buyout of Pacira Biosciences Inc. during its third-quarter earnings call Nov. 5, but the ...

Worldwide drug approvals totaled 38 in August 2026, compared to 39 in August 2025 and 52 in August 2024. Through the first eight months of 2026, global approvals totaled 337, down 6.4% from 360 during ...